Young-onset lung cancer: a clinician’s guide from diagnosis to survivorship

Introduction Young-onset lung cancer, most often defined as diagnosis at or before age 50, is increasingly recognized as a biologically, molecularly, and psychosocially distinct disease rather than an early-arising version of the cancer seen in older adults, yet clinical guidance in thoracic oncology has been built almost entirely from older, smoking-predominant populations. This gap matters because young patients are less likely to have smoked and are disproportionately enriched for targetable oncogenic driver mutations, a difference that reshapes diagnosis, treatment, and survivorship at every step. Methods We present a practical, five-part clinical guide for clinicians managing this population, moving from initial workup through long-term survivorship. The guide is intended for oncologists and multidisciplinary teams and is anchored to US guidelines, with reference to European recommendations. Literature was identified through targeted PubMed/MEDLINE searches, supplemented by current society guidelines, citation tracking, and author expertise, with priority given to phase III trials, society guidelines, population-based and institutional studies of patients aged ≤50 years, and adolescent and young adult-specific psychosocial and survivorship literature. As a narrative clinical guide, this review did not follow systematic review methodology. Results The guide addresses diagnostic delay and the molecular and imaging workup required given the high prevalence of driver mutations and brain metastases; time-sensitive pre-treatment referrals (genetic counseling, fertility preservation, social work, and psychosocial assessment) that must begin in parallel within the first clinical visits without delaying urgent treatment; stage- and mutation-directed therapy, including the growing role of adjuvant targeted therapy in this population; toxicities that are either more frequent in younger patients or carried over a much longer survivorship horizon; and survivorship planning encompassing early palliative care, fertility follow-up, financial toxicity, and return to work. Fertility, psychosocial health, and financial burden recur throughout rather than belonging to any single stage of care. Discussion This review is intended as a point-of-care resource built on a central premise: young adults with lung cancer require clinicians who treat molecular and psychosocial complexity as inseparable parts of the same clinical problem, not as sequential concerns addressed only after cancer-directed treatment ends.